News

Q1 2023 Newsletter – Recombinant metabolising enzymes

Hypha’s Q1 2023 newsletter – Recombinant metabolising enzymes

In our Q1 2023 newsletter we focus on Hypha’s recombinant enzymes, in particular new innovations to our PolyCYPs platform.

Biotransformation of pirfenidone to an oxidised metabolite which matches the CYP1A2 product.

More News

Senior Purification Chemist Job

Senior Purification Chemist Hypha Discovery has an exciting opportunity for an experienced purification chemist to join our team to work on metabolite synthesis and impurity

Q4 2023 Newsletter – Late-stage oxidation and deoxyfluorination

Hypha’s Q4 2023 Newsletter – Late-stage oxidation and deoxyfluorination In our Q4 2023 newsletter we give you a sneek peek of our new synthetic late-stage

Metabolites that Matter – Ivermectin

Metabolites that Matter – Ivermectin Ivermectin is a natural product derived broad spectrum antiparasitic drug, primarily deployed to combat parasitic worms in veterinary and human

Ready to begin? Our scientists are available to talk through your requirements

Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.

News

Q1 2023 Newsletter – Recombinant metabolising enzymes

Hypha’s Q1 2023 newsletter – Recombinant metabolising enzymes

Biotransformation of pirfenidone to an oxidised metabolite which matches the CYP1A2 product.

More News

Senior Purification Chemist Job

Q4 2023 Newsletter – Late-stage oxidation and deoxyfluorination

Metabolites that Matter – Ivermectin

Ready to begin? Our scientists are available to talk through your requirements

What We Do

Our Products

Our Science

Resources

Don't forget to subscribe to our newsletter and blog!